Recruiting

Intense radiation with or without hormone therapy for prostate cancer

Plain-English translation of NCT06111781 on ClinicalTrials.gov ↗ · Source last updated September 2026 · Translation generated August 2026 · How we translate trials

Read our Prostate Cancer research guide →

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing whether combining a newer form of radiation therapy with a short course of hormone-blocking medication called Relugolix works better than radiation alone for certain prostate cancers. The radiation is delivered in just 5 high-intensity sessions over 2 weeks (instead of the standard longer schedule), and the medication would be taken for about 30 days total. The goal is to improve cancer control while keeping side effects as low as possible.

Doctors know that hormone-blocking therapy can help intermediate-risk prostate cancer, but it causes bothersome side effects like hot flashes, fatigue, and sexual dysfunction. This trial tests whether using the medication for a very short time — just overlapping with radiation — can provide benefits without causing as many problems.

Do you qualify?

You likely qualify if…

you have been diagnosed with prostate cancer that is classified as intermediate-risk based on both traditional factors and genetic testing
you have a prostate-specific antigen (PSA) level between 0.2 and 20 ng/mL
your prostate volume is 80 cubic centimeters or smaller (measured by ultrasound or MRI)
you are able to swallow pills and willing to take daily medication if assigned to that group
you are willing to use birth control methods during treatment and for 4 months after

You likely don't qualify if…

you are currently taking medications that affect your heart's electrical rhythm
you have a history of long QT syndrome or certain heart rhythm problems
you have inflammatory bowel disease such as ulcerative colitis
you have had prior prostate surgery or radiation therapy
you are allergic to Relugolix or cannot tolerate hormone-blocking therapy

What participation looks like

You will be randomly assigned to receive either intense radiation therapy alone, or radiation therapy plus 30 days of hormone-blocking medication. The radiation is delivered in 5 appointments over 2 weeks. If you receive the medication, you will start taking it about 2 weeks before your first radiation appointment and continue for a total of 30 days. The study will track how well the cancer is controlled and how you feel over time, monitoring for side effects and quality of life.

AI-generated summary from trial data · Aug 7, 2026 · Not medical advice

Intense radiation with or without hormone therapy for prostate cancer

What is this trial?

Do you qualify?

What participation looks like

Trial locations(4 sites)